한글목차

두필루맙은 인간형 단클론성 IgG4 항체로, IL-4와 IL-13의 수용체 복합체에 공통적으로 존재하는 IL-4Rα 서브유닛에 특이적으로 결합하여 IL-4와 IL-13의 신호전달을 억제하는 인간형 단클론성 IgG4 항체입니다. IL-4 및 IL-13 신호전달을 억제합니다. 듀피센트의 임상 데이터에 따르면 IL-4와 IL-13은 아토피 피부염, 천식, 비강 용종증을 동반한 만성 비부비동염(CRSwNP), EoE에서 주요한 역할을 하는 제2형 염증의 주요 촉진인자로 알려져 있습니다. 두필루맙으로 IL-4Rα를 억제하면 염증성 사이토카인, 케모카인, 일산화질소, IgE의 방출을 포함한 IL-4 및 IL-13 사이토카인에 의한 염증반응이 억제됩니다. 두필루맙은 리제네론의 독자적인 VelocImmune 기술로 개발되었으며, VelocImmune은 완전 인간형 단클론 항체를 생산하는 독자적인 기술입니다.

회사에 따르면 듀피센트는 12세 이상의 EoE 환자에서 임상적으로 의미 있는 좋은 임상 3상 결과를 보인 최초이자 유일한 생물학적 제제입니다. 회사는 또한 활동성 EoE 소아 환자를 대상으로 한 임상 3상 시험(EoE KIDS)에서 듀피센트를 평가했습니다. 또한 FDA는 BTD, ODD, PR을 승인했습니다.

세계에서 호산구성 식도염(EoE)에 대한 광범위한 조사와 의료비 지출이 증가함에 따라 향후 수년간 호산구성 식도염(EoE) 시장 시나리오가 변화할 것으로 예상됩니다. 각 업체들은 질환을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 듀피센트의 우위에 영향을 미칠 수 있는 기회를 모색하고 있으며, EoE에 대한 다른 신흥 제품들이 듀피센트와 치열한 시장 경쟁을 벌일 것으로 예상됩니다. 출시되면 시장에 큰 영향을 미칠 것으로 예상되고 있습니다.

주요 7개국의 듀피젠트 시장에 대해 조사했으며, 호산구성 식도염(EoE) 치료제인 듀피젠트 시장의 개요와 2023-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 호산구성 식도염(EoE)에 대한 듀피젠트의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제상 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 듀피젠트 시장 평가

• EoE에 대한 듀피젠트의 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국에서 EoE에 대한 듀피젠트의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"DUPIXENT Drug Insight and Market Forecast - 2032" report provides comprehensive insights about DUPIXENT for Eosinophilic esophagitis (EoE) in the seven major markets. A detailed picture of the DUPIXENT for EoE in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DUPIXENT for EoE. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DUPIXENT market forecast analysis for EoE in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in EoE.

Drug Summary:

Dupilumab is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. It inhibits IL-4 signaling via the type I receptor and IL-4 and IL-13 signaling through the type II receptor. Data from DUPIXENT clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and EoE. Blocking IL-4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including the release of pro-inflammatory cytokines, chemokines, nitric oxide, and IgE. Dupilumab was invented using Regeneron's proprietary VelocImmune technology. VelocImmune is a unique technology for producing fully human monoclonal antibodies.

According to the company, DUPIXENT is the first and only biologic to show positive and clinically-meaningful Phase III results in patients 12 years and older with EoE. The company is also evaluating dupilumab in Phase III (EoE KIDS) study in pediatric patients with active EoE. Additionally, FDA has granted BTD, ODD, and PR.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DUPIXENT description, mechanism of action, dosage and administration, research and development activities in eosinophilic esophagitis (EoE).
• Elaborated details on DUPIXENT regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DUPIXENT research and development activities in EoE across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DUPIXENT.
• The report contains forecasted sales of DUPIXENT for EoE till 2032.
• Comprehensive coverage of the late-stage emerging therapies for EoE.
• The report also features the SWOT analysis with analyst views for DUPIXENT in EoE.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DUPIXENT Analytical Perspective by DelveInsight

In-depth DUPIXENT Market Assessment

This report provides a detailed market assessment of DUPIXENT for eosinophilic esophagitis (EoE) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

DUPIXENT Clinical Assessment

The report provides the clinical trials information of DUPIXENT for EoE covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for eosinophilic esophagitis (EoE) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DUPIXENT dominance.
• Other emerging products for EoE are expected to give tough market competition to DUPIXENT and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DUPIXENT in EoE.
• Our in-depth analysis of the forecasted sales data of DUPIXENT from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DUPIXENT in EoE.

Key Questions:

• What is the product type, route of administration and mechanism of action of DUPIXENT?
• What is the clinical trial status of the study related to DUPIXENT in eosinophilic esophagitis (EoE) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DUPIXENT development?
• What are the key designations that have been granted to DUPIXENT for EoE?
• What is the forecasted market scenario of DUPIXENT for EoE?
• What are the forecasted sales of DUPIXENT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to DUPIXENT for EoE?
• Which are the late-stage emerging therapies under development for the treatment of EoE?

Table of Contents

1. Report Introduction

2. DUPIXENT Overview in EoE

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DUPIXENT Market Assessment

• 5.1. Market Outlook of DUPIXENT in EoE
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DUPIXENT in the 7MM for EoE
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DUPIXENT in the United States for EoE
  • 5.3.2. Market Size of DUPIXENT in Germany for EoE
  • 5.3.3. Market Size of DUPIXENT in France for EoE
  • 5.3.4. Market Size of DUPIXENT in Italy for EoE
  • 5.3.5. Market Size of DUPIXENT in Spain for EoE
  • 5.3.6. Market Size of DUPIXENT in the United Kingdom for EoE
  • 5.3.7. Market Size of DUPIXENT in Japan for EoE

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options